** Shares of Orthocell fall as much as 10.1% to A$0.620, posting their biggest intraday pct loss since March 16, 2023
** Biotech firm says it will raise A$17 mln ($11.28 mln) via placement of 28.3 mln shares
** Issue price of A$0.60 per share is at a 13% discount to stock's last close
** Co says funds will be used to launch its nerve repair medical device Remplir in the United States
** Stock hits lowest level since Oct. 14
** About 1.2 mln shares change hands, 1.5x the 30-day avg
** Stock up 62.3% YTD, as of 0308 GMT
($1 = 1.5076 Australian dollars)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。